BUY Conviction3/5 Analysis quality65/100 now
The YouTuber recommends ATAI Life Sciences as a 'diversified play' in the psychedelic therapy market. Unlike Compass, ATAI has five drugs in clinical development, offering a broader pipeline and potentially safer bet due to diversification. It also has partial exposure to Compass through a stake and licensing agreement, and is backed by Peter Thiel. While currently pre-revenue and with patent protection varying by compound, its platform approach makes it an interesting, high-risk speculation.
“ATI is the platform bet. They're a clinical stage biotech company built like a venture portfolio. Not one drug, not two drugs, not three drugs, not four drugs. No, they have five drugs that are in clinical development.”